Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.

Frontiers in cardiovascular medicine·2026
Same author

Clinical-Pharmacological Drug Information Center of Hannover Medical School: Update From a Tertiary Care University Hospital (2022-2024).

Pharmacology research & perspectives·2026
Same author

Human vs. artificial intelligence: Physicians outperform ChatGPT in real-world pharmacotherapy counselling.

British journal of clinical pharmacology·2025
Same author

[Severe late-onset neutropenia after rituximab administration].

Zeitschrift fur Rheumatologie·2025
Same author

Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective Multicenter Observational Study.

Therapeutic drug monitoring·2024
Same author

Limited Value of HBV-RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative Hepatitis B Patients.

Journal of viral hepatitis·2024

Related Experiment Videos

[SSRI-associated bleeding risk].

Gesine Picksak1, Christoph Höner zu Siederdissen, Dirk O Stichtenoth

  • 1Zentralapotheke der Medizinischen Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover. Picksak.Gesine@mh-hannover.de

Medizinische Monatsschrift Fur Pharmazeuten
|June 26, 2010
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptake inhibitors (SSRI) can increase bleeding risk by reducing platelet aggregation. Combining SSRIs with antiplatelet drugs or NSAIDs further elevates this risk, especially gastrointestinal bleeding.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Clinical Medicine

Context:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
  • Antiplatelet drugs and nonsteroidal anti-inflammatory drugs (NSAIDs) are also commonly used medications.

Purpose:

  • To highlight the bleeding risk associated with SSRIs.
  • To emphasize the additive bleeding risk when SSRIs are combined with antiplatelet agents or NSAIDs.

Summary:

  • SSRIs reduce platelet aggregation, increasing bleeding risk.
  • Concurrent use of SSRIs with antiplatelet drugs or NSAIDs potentiates bleeding, particularly gastrointestinal bleeding.
  • Healthcare providers should consider bleeding as a significant adverse effect and drug interaction.

Impact:

  • Increases awareness among healthcare professionals regarding potential bleeding complications.
  • Promotes cautious prescribing of SSRIs in conjunction with other medications that affect hemostasis.
  • Aims to reduce the incidence of bleeding events in patients using these drug classes.